| CPC B01J 23/10 (2013.01) [A61K 33/244 (2019.01); A61P 39/06 (2018.01); C01F 17/235 (2020.01); C01F 17/30 (2020.01); C01P 2002/77 (2013.01); C01P 2004/64 (2013.01)] | 9 Claims |
|
1. A method of treating oxidative stress in a subject in need thereof, comprising:
delivering, to a subject in need thereof, a pharmaceutical composition, wherein the pharmaceutical composition includes a therapeutically effective amount of a compound, or a pharmaceutically acceptable salt of the compound, and a pharmaceutically acceptable carrier, to treat the oxidative stress,
wherein the compound comprises one or more molecular cerium-oxide nanocluster with cerium nuclearity of from 19 to 100 and having the formula [CexOy(OH)w(H2O)l(RCO2)z(L)m]n, CexOy(OH)w(H2O)l(RPO2)z(L)m]n or [CexOy(OH)w(H2O)l(RPO3)z(L)m]n, wherein x is from 19 to 100, wherein y is an integer number greater than 0, wherein l, m, n, w, z are 0 or an integer number, wherein R is selected from the group consisting of phenyl (Ph), CH3, CH3CH2, an aromatic group, a polyaromatic group, a substituted phenyl, a polyphenyl group, a linear or branched aliphatic groups, a substituted linear or branched aliphatic group, a linear or branched alicyclic group, and combinations thereof, wherein L is one or more neutral organic molecules, wherein the molecular cerium-oxide nanocluster composition has a ratio of Ce3+/Ce4+ of from 0.01 to 0.5.
|